Polaryx Therapeutics, Inc.
- Last sale
- Nov 12, 2026 · -0.53%
- Market cap
- $94.21M
- 49.85M shares
- Filings
- 36
—
—
—Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
—
—
—Q3 2026N/M FY25 yoy
Q3 2026+11.3% FY25 yoy
- $94.21M
- —
- —
- 12.4×
- —
- —
FY2025 figures · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Research And Development
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $6,266,000 | reported | |
| FY 2024 | 2024-12-31 | $2,811,000 | reported |
Pharmaceutical preparations
Polaryx Therapeutics, Inc. is the 290th largest of the 552 covered companies the SEC files under this code, by market cap. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
NRXPNRX Pharmaceuticals, Inc.$1.2M—2,336.5%$97.6MMSLESatellos Bioscience Inc.———$97.2MNBPNovaBridge Biosciences———$95.8M
PLYXPolaryx Therapeutics, Inc. (this company)———$94.2M
HURATuHURA Biosciences, Inc.$0.0——$94.0MANIXAnixa Biosciences Inc———$93.2MPMVPPMV Pharmaceuticals, Inc.———$92.2MRACCResearch Alliance Corp III———$91.9MGNLXGenelux Corp$8.0K0.0%401,812.5%$91.6MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Polaryx Therapeutics, Inc. · CIK 2075320 · Engraved from SEC EDGAR